Netflix Might Ready Something: What Investors Should Expect
As Netflix faces slowing growth, the question on investors' minds is simple: could the streamer be about to buy somet...
Accessible High Yield Savings Beginner Friendly
Overview of beginner-friendly HYSA options, focusing on accessibility, straightforward terms, and competitive rates.
24,631 articles
Bank Sent Fraud Alerts: Mall Case, Prevention Tips
When a shopper’s card data is compromised, banks often trigger rapid fraud alerts. This article breaks down how those...
Dinosaur Bones Market Roars as T-Rex Gus Sells for $50.1M
A T-Rex fossil nicknamed Gus sold for $50.1 million at auction, setting a new price record and signaling renewed dema...
Crypto Gambler Lost $1.5 Million After Argentina Beat England
A high-stakes crypto wager on a World Cup outcome went sour after Argentina edged England, with a lone bettor losing ...
Stolen Cards Being Loaded: Gift Card Fraud Reaches $1B
A quiet shift in crime is changing the way fraud happens at the checkout. When stolen cards being loaded into digital...
This Favorite Artificial Intelligence Stock to Buy Now
AI markets are crowded with flashy names, but the real backbone often lies in the companies that enable AI at scale. ...
Cogent Biosciences Stock 346% Surge Fueled by New Stake
A Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
Bitcoin Sell Pressure Easing: What It Means for Traders
Bitcoin has seen shifts in on-chain dynamics that suggest selling pressure may be easing. Yet large holders continue ...
Kodiak Sciences Stock 480% Rally: Big Fund Buy Explained
A prominent hedge fund unveiled a sizable Kodiak Sciences stake, triggering chatter about what the kodiak sciences st...
Forget NVIDIA: Micron 330% Rally Signals Cheap Tech Bet
Micron Technology has surged about 330% in the past year as AI workloads tighten memory supply. With DRAM pricing lik...
Therapeutics (TGTX) 2025 Earnings Outlook for Investors
TG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status